Biocon Biologics gets EU GMP certification from Ireland's HPRA

The company's new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru has received the certification following a GMP inspection in April 2022, a Biocon Biologics spokesperson said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/b0nSHAp
via IFTTT